Answers are grounded in this paper and cite their sources.
Systematic review investigates outcomes in graft survival after donor-specific antibody-negative transplantation, suggesting careful recipient selection is vital.
Background: Although it is true that donor-specific antibody (DSA) positivity is a highly validated risk factor of rejection and graft loss, it is not clear that a positive flow cytometry crossmatch (FCXM) without detectable DSA does have clinical implications. This is a valuable inter- organ transplantation and creates a dilemma in transplantation. Objective: To carry out a systematic literature review of the existing evidence on graft and patient outcomes after donor-specific antibody negative FCXM crossmatch positive transplantation. Methods: A literature search across on PubMed, MEDLINE, Embase, and Cochrane Library was performed to find out the studies assessing the outcomes in adult solid organ transplant patients with a DSA-negative and FCXM-positive result. The qualifying studies were randomised controlled trials, cohort studies, and observational studies that reported graft survival, patient survival, and outcome due to rejection. A qualitative narrative method was used to extract and synthesise the data due to the heterogeneity in study designs and immunological assessment measures. Results: Included in the review were mostly retrospective observational studies, primarily in kidney transplantation. In research, donor-specific antibody-negative FCXM-positive transplantation was correlated with associated with graft and patient survival, especially when risk-adapted immunosuppressive measures were used. Other reports showed increased early acute rejection, including antibody-mediated rejection; but the episode were usually reversible and they did not necessarily lead to poor long-term graft survival. Conclusion: The DSA-negative FCXM -positive transplantation is a transitional immunological risk phenotype and is safe to practice in the context of a carefully selected recipient. Personalized immunological evaluation and immunosuppression are required to maximize the results.
No takes yet. Share an insight, caveat, or question.
Zubair et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: